Not enough vitamin D: Health consequences for Canadians

Journal List > Can Fam Physician > v.53(5); May 2007

Can Fam Physician. 2007 May; 53(5): 841–854.

PMCID: PMC1949171

Not enough vitamin D

Health consequences for Canadians

Gerry Schwalfenberg, MD CCFP

Clinical lecturer in the Department of Family Medicine at the University of Alberta in Edmonton

Correspondence to: Dr Gerry Schwalfenberg, #301, 9509-156 St, Edmonton, AB T5P 4J5; telephone 780 484-1433; fax 780 489-1211; e-mail schwalfe/at/ualberta.ca

This article has been cited by other articles in PMC.

Abstract

OBJECTIVE

To review the evidence on vitamin D (VTD) insufficiency and deficiency from a Canadian perspective and to highlight some of the known and evolving implications of insufficiency or deficiency for health.

QUALITY OF EVIDENCE

PubMed was searched for articles on VTD insufficiency or deficiency and the role they play in various diseases and conditions. Level I and II evidence indicates that lack of VTD has a major role in short- and long-latency diseases.

MAIN MESSAGE

The long winters in Canada and lack of exposure to the sun contribute to lower levels of VTD among Canadians in late winter and spring. Currently recommended levels of fortification and supplementation are likely not high enough to restore adequate levels of VTD in the body. Repletion and maintenance therapy might be needed.

CONCLUSION

Many Canadians are at risk of VTD insufficiency or deficiency. Assessment of VTD status is important because optimal levels of VTD have been determined for various conditions. Low levels of VTD have negative implications for bone health and the health of other cell types.

RÉSUMÉ

OBJECTIF

Faire le point sur les données concernant l’insuffisance/ladéficience en vitamine D (VTD) d’un point de vue canadien et rappeler certaines des conséquences connues ou présentement à l’étude de ce problème pour la santé.

QUALITÉ DES PREUVES

On a consulté PubMed à la recherche d’articles sur l’insuffisance ou la déficience en VTD et sur leur rôle dans diverses maladies ou conditions. Des preuves de niveaux I et II indiquent qu’un manque de VTD joue un rôle important dans des maladies d’apparition rapide ou lente.

PRINCIPAL MESSAGE

Les longs hivers canadiens et le manque d’exposition au soleil contribuent à abaisser les niveaux de VTD chez les Canadiens en fin d’hiver et au printemps. Il est probable que les niveaux d’aliments enrichis ou de suppléments actuellement recommandés ne soient pas suffisants pour assurer des niveaux adéquats de VTD dans l’organisme. Il pourrait être nécessaire de restaurer et de maintenir les réserves.

CONCLUSION

Plusieurs Canadiens sont à risque d’insuffisance ou de déficience en VTD. L’évaluation du bilan de la VTD est important parce que des niveaux optimaux de VTD ont été établis pour diverses conditions. Les bas niveaux de VTD ont des effets négatifssur la santé de l’os et sur celle d’autres types de cellules.

This article reviews the guidelines for adequate intake of vitamin D (VTD), some of the basic physiology of VTD, and the relevance of the VTD receptor in some disease states. The definition of VTD status, and the prevalence, etiology, and treatment of inadequate status for various diseases will be discussed.

Quality of evidence

MEDLINE was searched using the words “vitamin D” and “vitamin D receptor” combined with “insufficiency,” “deficiency,” “osteoporosis,” “neuromuscular function,” “falls,” “cardiovascular disease,” “autoimmune disease,” “diabetes,” “cancer,” and “treatment.” Articles containing levels I, II, and III evidence were found. Original studies reviewed in this paper are listed in Table 1.¹^–⁵³

Table 1

Articles reviewed, number of subjects, design, outcomes, and comments

Past and current (1997) guidelines for adequate intake of vitamin D (VTD) are shown in Table 2.⁵⁴^–⁵⁷ Some have recommended that new guidelines for breastfed infants and people with osteoporosis are needed. New guidelines might be forthcoming after review of new data relating to our understanding of VTD and its role in chronic diseases with long latency periods.⁵⁸

Table 2

Canadian recommendations for adequate intake of vitamin D: 1975 to 2007.

Background

Vitamin D, a steroid hormone produced in the skin, has specific regulatory or functional effects on other parts of the body. Vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D (25[OH]D) and further hydroxylated in the kidney to 1,25-dihydroxyvitamin D. Hydroxylation in the kidney is regulated closely by parathyroid hormone (PTH), hypocalcemia, and hypophosphatemia and is inhibited by 1,25-dihydroxyvitamin D.⁵⁹ As well, 1,25-dihydroxyvitamin D (produced locally within cells) regulates gene transcription through nuclear high-affinity VTD receptors.⁶⁰ These receptors are found in the classic target organs: gut, bone, kidney, and parathyroid⁶¹ and many other tissues as well, such as brain, breast, colon, heart, pancreas, prostate, skin, and immune system. Vitamin D regulates cell growth and maturation, inhibits renin production, stimulates insulin secretion, and modulates the function of activated T- and B-lymphocytes and macrophages⁶²^,⁶³ (Table 3,¹^,²^,⁴^,³³^,⁵⁹^,⁶²^,⁶⁴^–⁸² Figure 1

Table 3

Studies of functions of vitamin D

Figure 1

Physiologic actions and potential benefits of vitamin D: References are listed in Tables 1,3, and 7.

Assessing VTD status

The major circulating metabolite of VTD is serum 25(OH)D, which has a half-life of between 10 and 19 days.⁵ It is the best indicator of VTD status and reflects levels from dietary intake and synthesis in the skin.⁸³ Levels <25 nmol/L are generally considered deficient; levels <80 nmol/L are considered insufficient.⁸⁴ There is some concern about the reliability and consistency of serum 25(OH)D laboratory results,⁸⁵ although there has been some improvement in the quality of tests in the past few years. The 2 main assays commercially available are listed in Table 4.⁸⁶^,⁸⁷ Liquid chromatography, which is the criterion standard, is not readily available.

Table 4

Assessment of vitamin D levels

Prevalence of VTD insufficiency or deficiency

Globally, VTD insufficiency or deficiency has been noted in many countries, from high school students in Iran⁷ to healthy western Canadians.⁸ Substantial seasonal variability has been noted in both Canada and Australia above and below the 37th parallel, respectively, with up to 97% of Canadians having inadequate levels of VTD at some time during the winter or spring.⁸^,⁹

Mothers and infants among native Canadian Cree in Manitoba have been found to be severely deficient in VTD, even in midsummer.¹⁰ In Inuvik, 48% of Inuit mothers were found to be deficient in VTD despite supplementation.¹¹ Seasonal variations were found in a Canadian study of healthy women in Toronto, Ont, and supplementation with 400 IU of VTD did not prevent insufficiency in the winter.¹² A study in Edmonton, Alta, showed that children and adolescents had low levels of VTD.¹³^,⁸⁸

Three studies in the United States, Finland, and Israel found that inpatients had insufficient or deficient levels of VTD.¹⁴^–¹⁶ Only 30% of patients in 3 Canadian long-term care facilities got adequate amounts of VTD through diet alone.¹⁷ Long-term care residents in Toronto had VTD deficiency that increased from 9% in the fall to 18% in the spring.¹⁸ Not only are inpatients at risk, but internal medical residents who work long hours indoors are also.¹⁹ A global study of VTD in postmenopausal women with osteoporosis showed that levels were deficient in 28.4% of them. There was no significant difference in levels among community-dwelling people and nursing-home patients. Deficiency increases with age; about 50% of those aged 70 and 80% of those aged 90 are deficient.⁸⁹ In a study of North American postmenopausal women, all taking an agent to treat or prevent osteoporosis and 59% taking =400 IU of VTD daily, 18% had levels below 50 nmol/L, and 52% had levels below 75 nmol/L. Despite supplementation, about 50% of women have suboptimal VTD levels.²⁰ A systematic review of 30 articles written in the past 10 years on VTD inadequacy in menopausal women supports these findings.²¹

Etiology of VTD deficiency and insufficiency

The risk factors that contribute to low levels of VTD are numerous and are summarized in Table 5.¹⁰^,²²^–²⁴^,⁹⁰^–¹¹⁰

Table 5

Risk factors for low serum vitamin D levels

Classic effects of VTD insufficiency or deficiency on disease

Vitamin D deficiency causes rickets in children and osteomalacia in adults. Rickets cases are still being reported in Canada.²⁵^,¹¹¹ Osteomalacia also still occurs, but its symptoms are much less specific and are easily missed.¹¹² Vitamin D is used to treat osteoporosis, but studies using calcium and 400 IU of VTD showed little effect on fractures. Most but not all studies using calcium and 700 to 800 IU of VTD did show a reduction in fractures.²⁶^–²⁸^,¹¹³ No benefit was seen from 1000 mg of calcium and 800 IU of VTD in a primary prevention trial²⁹ and a secondary prevention trial.³⁰^,¹¹⁴ Compliance was poor in both studies, and only 63% of patients were still taking treatment after 12 months in the former study, and only 1.1% of patients had baseline VTD levels taken in the latter study.

Supplementing with 400 IU of VTD for 8 weeks raised the measured 25(OH)D level by a mere 11 nmol/L in healthy men.⁵ To date, no studies have ensured that all subjects in treatment groups consistently had VTD levels >78 nmol/L. There is still great controversy over the benefit of VTD in fracture control.

Effects of insufficiency or deficiency on other disease states

Neuromuscular effects

Vitamin D acts on the VTD receptor in skeletal muscle cells by binding to the nuclear receptor and also to a cell membrane receptor, which results in numerous physiologic actions.⁷¹ Severe VTD deficiency is associated with muscle weakness, limb pain, and impaired physical function.³^,³¹^,¹¹⁵ A meta-analysis looking at ambulatory and institutionalized older patients found a reduction in falls of more than 20% with use of VTD. This effect was independent of calcium supplementation.³² In the most current multidose study of institutionalized older patients, supplementation with 800 IU of VTD resulted in a 72% reduction in falls.¹¹⁶ Another review found no such association.³ There is also evidence that idiopathic low back pain in patients with VTD deficiency markedly improves when VTD levels are restored.³⁵ Low levels of VTD are also common in patients with fibromyalgia and chronic refractory nonspecific musculoskeletal pain.³⁶^,³⁷^,¹¹⁷

Type 1 and 2 diabetes

A prospective study (begun in 1966) using 2000 IU of VTD in children resulted in an 80% reduction in development of type 1 diabetes during the next 30 years.³⁸ Studies using 400 IU of VTD early in life did not show a protective effect, and higher doses are being suggested.³⁹^,¹¹⁸ Increasing VTD levels from 25 to 75 nmol/L results in a 60% improvement in insulin sensitivity.⁴^,¹¹⁹ Low VTD levels were also shown to have a negative effect on beta cell function.¹²⁰ The improvement in insulin sensitivity was greater with VTD than improvement seen with either troglitzone (54%) or metformin (13%).⁴^,¹²¹

Multiple sclerosis and rheumatoid arthritis

Living at higher than 37° latitude increases the risk of developing multiple sclerosis by >100%. Taking a multivitamin with 400 IU of VTD reduces the risk by 40%.⁴⁴^,¹²² Women taking a multivitamin with 400 IU of VTD reduced their risk of developing rheumatoid arthritis by 40%.⁴⁵^,¹²²

Cardiovascular disease

Increased VTD levels suppress renin expression and renin levels and thus result in down-regulation of the renin-angiotensin system in animals.¹²³ Several mechanisms have been suggested for VTD’s protective role in cardiovascular disease.⁶⁸

Supplementation with calcium and VTD results in a substantial 9.3% decrease in systolic blood pressure and a 5.4% decrease in heart rate.⁴⁰ Supplementing with VTD substantially reduces C-reactive protein levels in critically ill patients.⁴¹ Low VTD levels might contribute to congestive heart failure.² In 3 large prospective cohort studies, however, higher intake of VTD was not associated with lower risk of hypertension.⁴² Clinical trials are needed to evaluate whether the morbidity and mortality associated with cardiovascular disease are reduced by optimal intake of oral VTD.

Cancer

Evidence from 63 observational studies indicates that inadequate VTD levels are a risk factor for certain types of cancer, such as breast, colon, ovarian, and prostate cancer.⁴³^,¹²⁴^,¹²⁵ Vitamin D and VTD analogues can induce cell death in some cancer cell lines.⁷⁴^,⁷⁵ Exposure to the sun might increase risk of skin cancer, but VTD has been shown to suppress growth and increase apop-tosis in melanoma cells.¹²⁶ The risks and benefits of sun exposure are a topic of hot debate at this time.⁴⁶^,¹²⁷^,¹²⁸

Psoriasis

Vitamin D analogues are used for psoriasis along with ultraviolet-B light. Treatment is successful because of the antiproliferative, immunosuppressive, and prodifferentiating effects of VTD.⁷³^,¹²⁹

Sources of VTD

The best way to increase VTD levels is to expose the skin to the sun. This has never been known to cause toxicity because of self-regulatory factors in the skin. Other sources of VTD are listed in Table 6.⁴⁷^,⁹¹^,¹³⁰^,¹³¹

Table 6

Sources of vitamin D

Treatment of VTD insufficiency and deficiency

The beneficial effects of VTD on various diseases are listed in Table 7.⁴^,³⁵^,³⁸^,⁴⁴^,⁴⁵^,⁴⁸^–⁵⁰^,⁷³^,⁷⁷^,⁷⁸^,⁹⁸^,¹¹¹^,¹¹²^,¹¹⁷^,¹³²^–¹⁴⁵ The question is, how can one vitamin influence so many disorders in a positive way? Just as abnormal levels of thyroid hormone can affect many cell systems, abnormal levels of VTD, a hormone, appear to affect many cell systems. Our understanding of the non-bone effects has greatly increased in the last 10 years.

Table 7

Benefits of vitamin D for various diseases, dosages, and comments

To maintain a healthy blood level of 25(OH)D (80 to 100 nmol/L), most healthy patients require at least 1000 IU of VTD each day if they do not get exposure to the sun.⁶³^,¹⁴⁶ Topping up to adequate levels quickly is the goal. Recommended repletion therapy consists of 50 000 IU of vitamin D2 weekly for 8 weeks or 2000 IU of vitamin D3 daily for 8 weeks.¹⁴⁷ Doses of 4000 IU of vitamin D3 have been used safely for several months, and there is evidence that doses up to 2000 IU/d can be considered safely (Table 8^,51^–⁵³^,¹⁴⁸^–¹⁵³).⁵²

Table 8

Source and dose of vitamin D, side effects, and potential toxicity:

Conclusion

Low levels of VTD are considered a major public health problem in Canada, especially during the winter. Those with risk factors should be screened for low 25(OH)D levels and repletion therapy instituted if needed. Researchers have estimated that the oral dose of vitamin D3 to attain and maintain 25(OH)D levels >80 nmol/L is 2200 IU/d if baseline levels are 20 to 40 nmol/L, 1800 IU/d if levels are 40 to 60 nmol/L, and 1160 IU/d if levels are between 60 and 80 nmol/L.⁶⁴

We need to ensure that patients have healthy blood levels of 25(OH)D to prevent levels of parathyroid hormone from rising and to maximize absorption of calcium, magnesium, and phosphate. Positive effects on bone are marginal at best unless patients consume at least 800 IU/d of VTD. The emerging and exciting role of the VTD receptor and the actions of VTD in maintaining health in other cell types have become more apparent during the last decade.

Notes

EDITOR’S KEY POINTS

Inadequate levels of vitamin D (VTD) have classically been associated with bone disorders, such as rickets, osteomalacia, and osteoporosis.
New research has demonstrated that VTD receptors are present throughout the body and that VTD has much broader effects than previously believed.
Current recommendations for VTD supplementation might be inadequate to ensure appropriate blood levels of VTD.

POINTS DE REPèRE DU RÉDACTEUR

Les niveaux inadéquats de vitamine D (VTD) ont généralement été associés à des anomalies osseuses comme le rachitisme, l’ostéomalacie et l’ostéoporose.
Les études récentes ont montré qu’il y a des récepteurs de VTD un peu partout dans l’organisme et que la VTD a des effets beaucoup plus étendus qu’on ne le croyait auparavant.
Les recommandations actuelles sur les suppléments de VTD pourraient donc ne pas assurer des niveaux sanguins adéquats de VTD.

Footnotes

This article has been peer reviewed.

Competing interests

None declared

References

1. Krejs GJ, Nicar MJ, Zerwekh JE, Norman DA, Kane MG, Pak CY. Effect of 1,25-dihydroxyvitamin D3 on calcium and magnesium absorption in the healthy human jejunum and ileum. Am J Med. 1983;75(6):973–6. [PubMed]

2. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105–12. [PubMed]

3. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc. 2003;51(9):1219–26. [PubMed]

4. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5. [PubMed]

5. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;8(3):222–30. [PubMed]

6. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439–43. [PubMed]

7. Moussavi M, Heidarpour R, Aminorraya A, Pournaghshband Z, Amini M. Prevalence of vitamin D deficiency in Isfahani high school students in 2004. Horm Res. 2005;64(3):144–8. [PubMed]

8. Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ. 2002;166(12):1517–24. [PubMed]

9. Pasco JA, Henry MJ, Kotowicz MA, Sanders KM, Seeman E, Pasco JR, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res. 2004;19(5):752–8. Epub 2004 Jan 19. [PubMed]

10. Lebrun JB, Moffatt ME, Mundy RJ, Sangster RK, Postl BD, Dooley JP, et al. Vitamin D deficiency in a Manitoba community. Can J Public Health. 1993;84(6):394–6. [PubMed]

11. Waiters B, Godel JC, Basu TK. Perinatal vitamin D and calcium status of northern Canadian mothers and their newborn infants. J Am Coll Nutr. 1999;18(2):122–6. [PubMed]

12. Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr. 2001;55(12):1091–7. [PubMed]

13. Roth DE, Martz P, Yeo R, Prosser C, Bell M, Jones AB. Are national vitamin D guidelines sufficient to maintain adequate blood levels in children? Can J Public Health. 2005;96(6):443–9. [PubMed]

14. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777–83. [PubMed]

15. Kauppinen-Makelin R, Tahtela R, Loyttyniemi E, Karkkainen J, Valimaki MJ. A high prevalence of hypovitaminosis D in Finnish medical in- and outpatients. J Intern Med. 2001;249(6):559–63. [PubMed]

16. Hochwald O, Harman-Boehm I, Castel H. Hypovitaminosis D among inpatients in a sunny country. Isr Med Assoc J. 2004;6(2):82–7. [PubMed]

17. Lee LT, Drake WM, Kendler DL. Intake of calcium and vitamin D in 3 Canadian long-term care facilities. J Am Diet Assoc. 2002;102(2):244–7. [PubMed]

18. Liu BA, Gordon M, Labranche JM, Murray TM, Vieth R, Shear NH. Seasonal prevalence of vitamin D deficiency in institutionalized older adults. J Am Geriatr Soc. 1997;45(5):598–603. [PubMed]

19. Haney EM, Stadler D, Bliziotes MM. Vitamin D insufficiency in internal medicine residents. Calcif Tissue Int. 2005;76(1):11–6. [PubMed]

20. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90(6):3215–24. [PubMed]

21. Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM. 2005;98(9):667–76. [PubMed]

22. Matsuoka LY, Wortsman J, Hanifan N, Holick MF. Chronic sunscreen use decreases circulating concentrations of 25-hydroxyvitamin D. A preliminary study. Arch Dermatol. 1988;124(12):1802–4. [PubMed]

23. Lo CW, Paris PW, Clemens TL, Nolan J, Holick MF. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985;42(4):644–9. [PubMed]

24. Jones DY, Miller KW, Koonsvitsky BP, Ebert ML, Lin PY, Jones MB, et al. Serum 25-hydroxyvitamin D concentrations of free-living subjects consuming Olestra. Am J Clin Nutr. 1991;53(5):1281–7. [PubMed]

25. Binet A, Kooh SW. Persistence of Vitamin D-deficiency rickets in Toronto in the 1990s. Can J Public Health. 1996;87(4):227–30. [PubMed]

26. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293(18):2257–64. [PubMed]

27. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–6. [PubMed]

28. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13(3):257–64. [PubMed]

29. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ. 2005;330(7498):1003. [PubMed]

30. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621–8. [PubMed]

31. Dhesi JK, Jackson SH, Bearne LM, Moniz C, Hurley MV, Swift CG, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. 2004;33(6):589–95. [PubMed]

32. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291(16):1999–2006. [PubMed]

33. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr. 2004;80(3):752–8. [PubMed]

34. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis. 2005;20(3):187–92. [PubMed]

35. Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. Spine. 2003;28(2):177–9. [PubMed]

36. Al-Allaf AW, Mole PA, Paterson CR, Pullar T. Bone health in patients with fibro-myalgia. Rheumatology (Oxford). 2003;42(10):1202–6. [PubMed]

37. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78(12):1463–70. [PubMed]

38. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(9292):1500–3. [PubMed]

39. Harris SS. Vitamin D in type 1 diabetes prevention. J Nutr. 2005;135(2):323–5. [PubMed]

40. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86(4):1633–7. [PubMed]

41. Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab. 2003;88(10):4623–32. [PubMed]

42. Forman JP, Bischoff-Ferrari HA, Willett WC, Stampfer MJ, Curhan GC. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension. 2005;46(4):676–82. [PubMed]

43. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006;96(2):252–61. [PubMed]

44. Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–5. [PubMed]

45. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum. 2004;50(1):72–7. [PubMed]

46. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst. 2005;97(3):195–9. [PubMed]

47. Kennedy C, Bajdik CD, Willemze R, De Gruijl FR, Bouwes Bavinck JN. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol. 2003;120(6):1087–93. [PubMed]

48. Linday LA, Shindledecker RD, Tapia-Mendoza J, Dolitsky JN. Effect of daily cod liver oil and a multivitamin-mineral supplement with selenium on upper respiratory tract pediatric visits by young, inner-city, Latino children: randomized pediatric sites. Ann Otol Rhinol Laryngol. 2004;113(11):891–901. [PubMed]

49. Wayse V, Yousafzai A, Mogale K, Filteau S. Association of subclinical vitamin D deficiency with severe acute lower respiratory infection in Indian children under 5 y. Eur J Clin Nutr. 2004;58(4):563–7. [PubMed]

50. Krall EA, Wehler C, Garcia RI, Harris SS, Dawson-Hughes B. Calcium and vitamin D supplements reduce tooth loss in the elderly. Am J Med. 2001;111(6):452–6. [PubMed]

51. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J. 2004;3:8. [PubMed]

52. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr. 2001;73(2):288–94. [PubMed]

53. Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med. 2005;165(14):1618–23. [PubMed]

54. Committee for the revision of Dietary Standards for Canada. Dietary standard for Canada. Ottawa, Ont: Canadian Publishing Centre, Supply and Services Canada; 1976.

55. Committee for the revision of Dietary Standards for Canada. Dietary standard for Canada. Recommended intakes for Canadians. Ottawa, Ont: Canadian Publishing Centre, Supply and Services Canada; 1983.

56. Scientific Review Committee. Nutrition recommendations. Ottawa, Ont: Canadian Government Publishing Centre, Supply and Services Canada; 1990.

57. Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academies Press; 1997.

58. Whiting SJ, Calvo MS. Dietary recommendations for vitamin D: a critical need for functional end points to establish an estimated average requirement. J Nutr. 2005;135(2):304–9. [PubMed]

59. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8. [PubMed]

60. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S–96S. [PubMed]

61. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihy-droxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206(4423):1188–90. [PubMed]

62. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8–28. [PubMed]

63. Holick MF. The influence of vitamin D on bone health across the life cycle. J Nutr. 2005;135(11):2726S–7S. [PubMed]

64. Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1–2):13–9. [PubMed]

65. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22(2):142–6. [PubMed]

66. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294(18):2336–41. [PubMed]

67. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab. 2001;86(3):1212–21. [PubMed]

68. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr. 2005;94(4):483–92. [PubMed]

69. Vieth R, Kimball S. Vitamin D in congestive heart failure. Am J Clin Nutr. 2006;83(4):731–2. [PubMed]

70. Zittermann A, Schleithoff SS, Koerfer R. Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev. 2006;11(1):25–33. [PubMed]

71. Pedrosa MA, Castro ML. Role of vitamin D in the neuro-muscular function. Arq Bras Endocrinol Metabol. 2005;49(4):495–502. [PubMed]

72. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med. 2006;166(4):424–30. [PubMed]

73. Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. Exp Dermatol. 2004;13(Suppl 4):11–5. [PubMed]

74. Sergeev IN. Calcium signaling in cancer and vitamin D. J Steroid Biochem Mol Biol. 2005;97(1–2):145–51. [PubMed]

75. Elias J, Marian B, Edling C, Lachmann B, Noe CR, Rolf SH. Induction of apop-tosis by vitamin D metabolites and analogs in a glioma cell line. Recent Results Cancer Res. 2003;164:319–32. [PubMed]

76. Chatterjee M. Vitamin D and genomic stability. Mutat Res. 2001;475(1–2):69–87. [PubMed]

77. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129–40. [PubMed]

78. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D–mediated human antimicrobial response. Science. 2006;311(5768):1770–3. [PubMed]

79. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–77. [PubMed]

80. Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–11. doi: 10.1172/JCI30142. [PubMed]

81. Komatsuzawa H, Ouhara K, Yamada S, Fujiwara T, Sayama K, Hashimoto K, et al. Innate defences against methicillin-resistant Staphylococcus aureus (MRSA) infection. J Pathol. 2006;208(2):249–60. [PubMed]

82. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol. 2005;125(1):108–15. [PubMed]

83. Hollis BW. Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. Calcif Tissue Int. 1996;58(1):4–5. [PubMed]

84. Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005;135(2):332–7. [PubMed]

85. Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004;89(7):3152–7. [PubMed]

86. Looker AC. Body fat and vitamin D status in black versus white women. J Clin Endocrinol Metab. 2005;90(2):635–40. [PubMed]

87. Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem. 2000;46(10):1657–61. [PubMed]

88. Harkness LS, Bonny AE. Calcium and vitamin D status in the adolescent: key roles for bone, body weight, glucose tolerance, and estrogen biosynthesis. J Pediatr Adolesc Gynecol. 2005;18(5):305–11. [PubMed]

89. Reginster JY. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin. 2005;21(4):579–86. [PubMed]

90. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67(2):373–8. [PubMed]

91. Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135(11):2739S–48S. [PubMed]

92. Lehmann B. The vitamin D3 pathway in human skin and its role for regulation of biological processes. Photochem Photobiol. 2005;81(6):1246–51. [PubMed]

93. Lamberg-Allardt C, Karkkainen M, Seppanen R, Bistrom H. Low serum 25-hydroxyvitamin D concentrations and secondary hyperparathyroidism in middle-aged white strict vegetarians. Am J Clin Nutr. 1993;58(5):684–9. [PubMed]

94. Holick MF. Vitamin D deficiency in obesity and health consequences. Curr Opin Endocrinol Diabetes Obes. 2006;13(5):412–8.

95. Dawodu A, Agarwal M, Hossain M, Kochiyil J, Zayed R. Hypovitaminosis D and vitamin D deficiency in exclusively breast-feeding infants and their mothers in summer: a justification for vitamin D supplementation of breast-feeding infants. J Pediatr. 2003;142(2):169–73. [PubMed]

96. Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr. 2004;80(6 Suppl):1752S–8S. [PubMed]

97. Pawley N, Bishop NJ. Prenatal and infant predictors of bone health: the influence of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1748S–51S. [PubMed]

98. Rutz HP. Hypovitaminosis D, insulin resistance and hypertension in pregnancy. Eur J Clin Nutr. 2005;59(6):805–6. [PubMed]

99. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr. 1998;79(4):315–27. [PubMed]

100. Hollis BW, Wagner CL. Assessment of dietary vitamin D requirements during pregnancy and lactation. Am J Clin Nutr. 2004;79(5):717–26. [PubMed]

101. Cerimele D, Celleno L, Serri F. Physiological changes in ageing skin. Br J Dermatol. 1990;122(Suppl 35):13–20. [PubMed]

102. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. J Nutr. 2005;135(2):310–6. [PubMed]

103. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76(4):1536–8. [PubMed]

104. Ramsay RE, Slater JD. Effects of antiepileptic drugs on hormones. Epilepsia. 1991;32(Suppl 6):S60–7. [PubMed]

105. Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250(2):144–53. [PubMed]

106. Odes HS, Fraser GM, Krugliak P, Lamprecht SA, Shany S. Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion. 1990;46(2):61–4. [PubMed]

107. Rosenblatt S, Chanley JD, Segal RL. The effect of lithium on vitamin D metabolism. Biol Psychiatry. 1989;26(2):206–8. [PubMed]

108. Czerwienska B, Kokot F, Franek E, Irzyniec T, Wiecek A. Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects. Pol Arch Med Wewn. 2004;112(6):1415–23. [PubMed]

109. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2(1):10–32. [PubMed]

110. Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study. J Clin Endocrinol Metab. 1998;83(1):169–73. [PubMed]

111. Wharton B, Bishop N. Rickets. Lancet. 2003;362(9393):1389–400. [PubMed]

112. Primary vitamin D deficiency in adults. Drug Ther Bull. 2006;44(4):25–9. [PubMed]

113. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119(4 Suppl 1):S3–S11. [PubMed]

114. Francis RM. Calcium, vitamin D and involutional osteoporosis. Curr Opin Clin Nutr Metab Care. 2006;9(1):13–7. [PubMed]

115. Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med. 2005;26(3):203–19. [PubMed]

116. Broe KE, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc. 2007;55(2):234–9. [PubMed]

117. De Torrente de la Jara G, Pecoud A, Favrat B. Female asylum seekers with musculoskeletal pain: the importance of diagnosis and treatment of hypovita-minosis D. BMC Fam Pract. 2006;7:4. [PubMed]

118. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab. 2005;16(6):261–6. [PubMed]

119. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209(4458):823–5. [PubMed]

120. Luong K, Nguyen LT, Nguyen DN. The role of vitamin D in protecting type 1 diabetes mellitus. Diabetes Metab Res Rev. 2005;21(4):338–46. [PubMed]

121. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338(13):867–72. [PubMed]

122. Ponsonby AL, Lucas RM, van der Mei IA. UVR, vitamin D and three auto-immune diseases—multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol. 2005;81(6):1267–75. [PubMed]

123. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38. [PubMed]

124. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92(1):49–59. [PubMed]

125. Gross MD. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J Nutr. 2005;135(2):326–31. [PubMed]

126. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol. 2002;147(2):197–213. [PubMed]

127. Corona R. Another paradigm lost or just a paradox? Arch Dermatol. 2005;141(12):1587–8. [PubMed]

128. Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. 2006;92(1):132–9. [PubMed]

129. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 2004;215(1–2):31–8. [PubMed]

130. Melanson SF, Lewandrowski EL, Flood JG, Lewandrowski KB. Measurement of organochlorines in commercial over-the-counter fish oil preparations: implications for dietary and therapeutic recommendations for omega-3 fatty acids and a review of the literature. Arch Pathol Lab Med. 2005;129(1):74–7. [PubMed]

131. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? Arch Pathol Lab Med. 2003;127(12):1603–5. [PubMed]

132. Bouillon R, Verstuyf A, Mathieu C, Van Cromphaut S, Masuyama R, Dehaes P, et al. Vitamin D resistance. Best Pract Res Clin Endocrinol Metab. 2006;20(4):627–45. [PubMed]

133. Mannion CA, Gray-Donald K, Koski KG. Association of low intake of milk and vitamin D during pregnancy with decreased birth weight. CMAJ. 2006;174(9):1273–7. [PubMed]

134. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430–5. [PubMed]

135. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165(11):1246–52. [PubMed]

136. Gorham ED, Garland CF, Grant WB, Morh SB, Lipkin M, Newmark HL, et al. Optimal vitamin D status for colorectal cancer prevention; a quantitative meta analysis. Am J Prev Med. 2007;32(3):210–6. [PubMed]

137. Slattery ML, Neuhausen SL, Hoffman M, Caan B, Curtin K, Ma KN, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer. 2004;111(5):750–6. [PubMed]

138. Garland CF, Garland FC, Gorham ED. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr. 1991;54(1 Suppl):193S–201S. [PubMed]

139. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst. 2002;94(6):437–46. [PubMed]

140. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2004;108(1):104–8. [PubMed]

141. Vieth R. Enzyme kinetics hypothesis to explain the U-shaped risk curve for prostate cancer vs. 25-hydroxyvitamin D in Nordic countries. Int J Cancer. 2004;111(3):468. author reply 469. [PubMed]

142. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1688–95. [PubMed]

143. Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D status and breast cancer risk. Anticancer Res. 2006;26(4A):2573–80. [PubMed]

144. Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med. 2002;59(4):257–62. [PubMed]

145. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994;23(6):1133–6. [PubMed]

146. Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. J Steroid Biochem Mol Biol. 2004;89–90(1–5):575–9.

147. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(6 Suppl):1678S–88S. [PubMed]

148. Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest. 1996;109(2):535–9. [PubMed]

149. Tuohy KA, Steinman TI. Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn’s disease. Am J Kidney Dis. 2005;45(1):3–6.

150. Pronicka E, Rowinska E, Kulczycka H, Lukaszkiewicz J, Lorenc R, Janas R. Persistent hypercalciuria and elevated 25-hydroxyvitamin D3 in children with infantile hypercalcaemia. Pediatr Nephrol. 1997;11(1):2–6. [PubMed]

151. Better OS, Shabtai M, Kedar S, Melamud A, Berenheim J, Chaimovitz C. Increased incidence of nephrolithiasis (N) in lifeguards (LG) in Israel. Adv Exp Med Biol. 1980;128:467–72. [PubMed]

152. Misselwitz J, Hesse CF, Markestad T. Nephrocalcinosis, hypercalciuria and elevated serum levels of 1,25-dihydroxyvitamin D in children. Possible link to vitamin D toxicity. Acta Paediatr Scand. 1990;79(6–7):637–43. [PubMed]

153. Adams JS, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med. 1997;127(3):203–6. [PubMed]

Formats:

PubMed articles by these authors

PubMed related articles

Recent Activity

Links

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information